Summary of 2026 conference talks

Rethinking Youth Gender Medicine: Summaries of Talks

These are short summaries of the talks given at Rethinking Youth Gender Medicine, held at UCL in London on 5 and 6 July 2026 and organised by CAN-SG and SEGM. They follow the order of the conference programme. Question-and-answer sessions and the closing panel discussion are not included.

Day one: Aetiologies, evidence, research and ethics

Opening

Dr Louise Irvine: Introduction to the conference

Dr Louise Irvine, Co-Chair of CAN-SG, welcomed delegates, the live-stream audience and speakers from the USA, Canada and Australia. She said the conference aimed to look deeper and wider at youth gender medicine, and to understand how medical and surgical intervention came to be widely accepted as the answer for children with deep social, emotional and psychological problems. The first day would ask how we got here. The second would look at social and cultural pressures, including social transition, and then at positive approaches, with a focus on therapy and on listening to detransitioners.

Baroness Dianne Hayter: Welcome and opening speech

Baroness Hayter praised UCL for hosting the conference despite efforts to stop it. These included a small protest outside and The Psychologist refusing to carry an advertisement. Clinicians simply wanted to discuss the evidence, and families needed confidence that any intervention was in a child’s long-term interest. She noted the irony of NHS England now warning about health misinformation online. Politicians can withstand intimidation, she said, but closing down clinical debate threatens the children professionals must safeguard. She doubted that young people can give informed consent to treatments affecting their fertility, sexual function and development, and opposed the puberty blocker trial. She also noted that there is still no NHS service for detransitioners. She warned that the draft conversion practices bill could have a chilling effect on therapists and parents, and urged delegates to submit evidence to the parliamentary committee that will scrutinise it.

Maeve Halligan: Why this debate is vital for children and young people

Maeve Halligan, 23, of the Cambridge University Society of Women, a single-sex student society set up this academic year, described the support the society received from medical professionals. She found it saddening that so many felt silenced, and that clinicians are forced into activism simply by doing their jobs. Children, she argued, cannot meaningfully consent to life-changing treatment such as puberty blockers, cross-sex hormones or surgery. Having been a teenager very recently, she knew how often young people change their minds. Discomfort with one’s body is a normal part of growing up female, and society should change so that girls do not feel they must alter their bodies. Not everyone will be able to say “when this is all over”, she said, because for those medicalised young the harm is irreversible and lifelong. She was worried about the puberty blocker trial but encouraged by the conference, because when people come together, things change.

Origins and aetiology (chair: Dr David Bell)

Zhenya Abbruzzese: A brief history of gender medicine and the rise of the Dutch protocol

Zhenya Abbruzzese, co-founder of the Society for Evidence-Based Gender Medicine, traced the history behind the Dutch protocol, the basis of paediatric gender transition. It began with Magnus Hirschfeld in 1920s Germany and continued with Christine Jorgensen’s widely publicised 1950s “sex change”. Jorgensen’s own doctors had originally seen the case as a gay man seeking castration. The Netherlands became the hub for transition. A 1980s follow-up there found subjective satisfaction but no objective improvement, a worrying suicide signal and heavy loss to follow-up.

Peggy Cohen-Kettenis then lowered the age for hormones from 18 to 16. After seeing a patient already treated with blockers, the team added puberty blockers from age 12. Abbruzzese said the protocol’s key published finding, a dramatic fall in gender dysphoria, is an artefact of the Utrecht scale. Patients answered the female version before treatment and the male version after, which inverts the questions. Other mental health gains were small, and adverse outcomes, including a death after surgery, were left out of the final analysis.

She also challenged the claims that transition prevents suicide and that psychotherapy is ineffective. WPATH’s evidence for the latter dates from the 1960s, when lobotomy was considered effective treatment. Finally, she criticised the Dutch Health Council’s recent re-review as conflicted and contradictory.

Professor Michael Biggs: How the availability of puberty suppression transformed the social, cultural and medical landscape

Professor Michael Biggs, a sociologist at the University of Oxford, argued that puberty blockers created the modern “transgender child”. Cross-sex behaviour in children has long existed, but social transition at school was vanishingly rare before the 1990s, and claimed historical cases are mostly adults’ retrospective accounts. Academic writing on transgender children was almost non-existent before 2000, and more than 100 articles a year are now published. Over that time the wording has shifted from “children with gender dysphoria” to “transgender children”. The earliest uses of such terms came from the Dutch pioneers of puberty blockers. Peggy Cohen-Kettenis’s 1998 case study of a single patient, “B”, is the most cited article.

Blockers spread rapidly, into WPATH’s 2001 standards of care on the strength of that one case, and into documentaries such as those on Valentijn de Hingh and Jazz Jennings in 2007. Biggs argued that blockers make early social transition feasible, because a child cannot live as the opposite sex once puberty begins. Social transition in turn locks in the identity. Blockers also recast puberty as a preventable disease, to the point where allowing it was described as unethical. Alongside Judith Butler’s queer theory and the internet, he concluded, puberty blockers created 21st-century transgenderism.

Professor Alex Byrne: Diagnoses in gender medicine. How does language shape what we understand and what we’re allowed to question?

Professor Alex Byrne, a philosopher at MIT, explained that most psychiatric diagnoses describe syndromes rather than explaining symptoms. The DSM-III diagnosis of 1980 described gender identity disorder as a profound disturbance of the sense of maleness or femaleness. DSM-5 (2013) broke with this. It separated a non-pathological “gender incongruence”, in effect simply being transgender, from the distress that may be “associated with” it, and only that distress is diagnosed as gender dysphoria. ICD-11 (2022) went further. Its diagnosis of gender incongruence requires no distress at all and sits in a chapter on sexual health. A WHO working group said health services are needed even without distress, which means treatment serves embodiment goals rather than any illness.

Byrne drew a close parallel with “ego-dystonic homosexuality” in DSM-III, a non-pathological condition diagnosed only when it caused distress. It was removed in 1987, partly because it gave a rationale for conversion practices, and he argued the same objections apply to gender dysphoria. The framework is also inconsistent. Most children with gender dysphoria desist, which shows incongruence can be transient. Yet gender medicine treats being transgender as stable, and DSM-5-TR quietly removed any suggestion of impermanence. He concluded that separating distress from incongruence was a serious mistake.

Evidence, uncertainty, and risk from childhood into adulthood (chair: Dr Louise Irvine)

Dr Alison Clayton: Diagnostic, aetiological and prognostic uncertainty in youth gender medicine

Dr Alison Clayton used the intensity of professional debate as a measure of diagnostic uncertainty. Whether gender incongruence is a normal variant or a mental disorder is contested. ICD-11 placed it outside mental disorders mainly to secure access to treatment, and WPATH’s SOC 8 discourages diagnosis altogether. Yet gender distress can be part of other conditions, notably complex trauma. She cited Ovid’s Caenis, who sought a male body after being raped, and a modern case of a girl who wanted to be a boy after her mother was murdered. Some clinicians condemn any talk of causes as conversion therapy while promoting their own unvalidated theory of an innate gender self.

Presentations have changed sharply. Referrals have surged, the patient group has shifted, and childhood gender distress that once usually resolved now often persists, especially after social transition. Adolescent-onset cases appear unstable. Clayton compared this to the multiple personality disorder epidemic that followed the book Sybil, where distress was genuine but shaped by culture, clinicians and the media. Genes do not rule out such cultural shaping. She also identified confusions in DSM-5-TR. It defines sex and gender separately, then conflates them. It is ambiguous about whether distress is required. Its criteria could even diagnose a girl rejecting restrictive sex roles. She concluded that uncertainty must be acknowledged, and questioning allowed.

Dr Scot Glasberg: Breaking the mould. How the American Society of Plastic Surgeons decided to put evidence first

Dr Scot Glasberg, past president of the American Society of Plastic Surgeons (ASPS), described how ASPS came to follow the evidence. Medical societies had deferred to “consensus”. When gender surgeons asked ASPS for guidelines around 2021, WPATH ignored its approaches for a year, then refused to share its methodology, citing litigation. Discovery in an Alabama court case later revealed that WPATH had suppressed systematic reviews it commissioned from Johns Hopkins. In 2024 ASPS warned members that the evidence was of low certainty. Glasberg postponed a planned panel with Hilary Cass under pressure, a decision he still regrets.

In February 2026 ASPS recommended delaying gender surgery until at least 19, the age at which bodies such as the American Academy of Pediatrics say adolescence ends. It cited insufficient evidence of a favourable risk-benefit ratio. The statement also stressed surgeons’ responsibility for mental health evaluation, opposed criminalisation and acknowledged young people’s real distress. The AMA initially agreed, then backtracked. Despite a petition against the change in policy signed by 350 of around 9,000 ASPS members, only one surgeon resigned. Dr Glasberg cited the Cass and HHS reviews and a Finnish study showing mental health worsened after treatment, and urged following the Nordic countries. Patient autonomy and shared decision-making do not override evidence. Detransition care is now the fastest-growing part of his practice. ASPS, he said, had not broken from medicine but returned to it.

Dr Ray Zhang: Clinical trials in gender medicine. Do risks outweigh benefits?

Dr Ray Zhang, a clinical epidemiologist at Evidence Bridge, asked whether there is genuine equipoise, meaning honest uncertainty about which option is better, to justify clinical trials of paediatric medical transition. Systematic reviews, including those for the Cass Review and the US HHS review, found very low-certainty evidence on both benefits and harms. But Zhang argued that such reviews are not well suited to assessing harm. Evidence-based medicine emphasises human epidemiological studies. Seen on its side, the evidence pyramid is a sequence of screening stages, from basic science through preclinical work to trials, that weeds out risky options. Paediatric gender medicine skipped those stages, so looking only at clinical studies is a “streetlight effect”, searching only where the light is good.

He noted that bodies such as the International Agency for Research on Cancer already judge harms from animal and mechanistic evidence. Benefits such as better quality of life or fewer suicides need human studies. Harms to fertility, organ development and reproductive function can reasonably be inferred from established science. Loss to follow-up also hides harms, and offering fertility preservation tacitly admits fertility will be compromised. He concluded that the benefit is uncertain but harm is reasonably expected, so there is no genuine equipoise.

Research (chair: Professor Alice Sullivan)

Professor Alice Sullivan: Barriers to research in gender medicine

Alice Sullivan, professor of sociology at UCL, drew on the second report of her government-commissioned Sullivan Review. That report included an open call for evidence, which received 140 submissions from academics. She argued that the barriers to research in gender medicine are part of a much wider problem that affects every discipline.

She said well-publicised no-platforming is only the tip of the iceberg. Beneath it lie campaigns of harassment and denunciation, like those that led Kathleen Stock to leave Sussex and Carole Hooven to leave Harvard. Journals also face activist pressure, as with the attempt to retract Lisa Littman’s paper on rapid-onset gender dysphoria, and some journals’ guidelines, such as The Lancet’s, describe sex as a spectrum. Michele Moore described needing security guards to speak and facing legal threats from the Tavistock over a book.

More mundane but widespread are bureaucratic barriers. These include ethics committees requiring high-risk review just to record participants’ sex, and organisations that aren’t allowed to collect data on sex. The result is widespread self-censorship.

Sullivan rejected the idea that “both sides” are to blame. She pointed to activist campaigns, often coordinated through EDI roles and staff networks, and to universities’ failure to deal with them. She said nothing will change until harassers stop getting away with it, and that medicine is just as exposed to these pressures as other fields.

Professor Sallie Baxendale: The effect of puberty blockers on the adolescent brain

Professor Sallie Baxendale, Professor of Clinical Neuropsychology at UCL, explained that brain development follows pre-programmed “critical windows”. If the right input is missing during a window, the brain moves on and that function develops less well. Puberty is one such window. Driven by sex hormones, it prunes and rewires the brain and develops the prefrontal cortex, which supports executive function, emotional regulation and social cognition. It differs between males and females.

Animal studies consistently show that puberty blockers impair learning, social behaviour and stress responses, with sex-specific effects and changes in brain structure. There is no evidence these effects reverse. In sheep, impaired spatial memory persisted after treatment stopped.

Human studies are few and weak. In girls treated for precocious puberty, IQ fell by about seven points on average. A single case study showed a fall in IQ from 101 to 86. One study is often cited as showing no harm, yet it found poorer executive function. Another lost 40% of participants and replaced the IQ outcome with educational level.

She concluded that claims that blockers are “fully reversible” have no evidence behind them. A meaningful trial would need to account for sex, pubertal stage, length of treatment and later treatments, and to follow participants into adulthood. She closed by setting out the stated rationales for the Pathways trial, to be weighed against these risks.

Dr Sinead Helyar: Pathways puberty blocker trial. Safety and ethics

Dr Sinead Helyar, a registered nurse who works in clinical trials, argued that the Pathways puberty blocker trial does not meet the ethical and legal standards governing research. Those standards run from the Nuremberg Code and the Declaration of Helsinki to Good Clinical Practice. They are written into UK law through the Medicines for Human Use (Clinical Trials) Regulations 2004, which state that the rights, safety and wellbeing of participants come first. The trial’s link to the Cass Review does not exempt it.

She highlighted Principle 14 of those regulations, which requires trials in children to minimise foreseeable risks to the child’s development. The trial, she said, does the opposite. She compared it to the infected blood trials, whose ethical failures are now widely condemned.

Children under 16 cannot consent to a drug trial, and parents cannot meaningfully consent to risks such as infertility. The trial tests timing rather than treatment, so it may simply favour early blockers. It also relies on uncertain diagnoses and unvalidated short-term outcomes. Its risks outweigh its likely benefits, and its subjects are physically healthy children. Less invasive research should come first. This includes NHS data linkage studies, psychological interventions, animal studies and existing safety data from other uses of these drugs.

Hormonal interventions in gender medicine. What are the harms?

Dr Hannah, specialist registrar in clinical pharmacology, began by pointing out how much is still unknown about normal puberty. This includes what triggers it, what controls its timing and pace, and how that timing shapes brain development.

She outlined the drugs used. Puberty blockers (GnRH agonists) work by overstimulating the pituitary until it shuts down sex hormone production. They were developed for other conditions such as prostate cancer and endometriosis. They are followed by cross-sex hormones and other drugs that act on sex hormones. Because sex hormones affect bone, muscle, metabolism, the heart, mood and fertility, removing them has predictable effects. These include lower bone density, worse metabolic health, slower growth, low mood, QT prolongation, menopause-like symptoms in females and halted genital development. She stressed that these effects are not controversial.

Less is known about effects on brain and psychosocial development, whether blockers make gender dysphoria more likely to persist, and long-term effects on sexual function, fertility and heart health. Ryan said the reason is that clinicians have collected little data. She criticised two recent studies on sexual function for drawing confident conclusions from very small samples. She also flagged emerging concern about acute mental health crises after starting testosterone.

Other reasons for insufficient evidence for the harms she listed include the lack of trials, multiple overlapping treatments, DIY hormones and weak systems for reporting adverse effects.

Ethical challenges in youth gender medicine (chair: Zhenya Abbruzzese)

Professor Moti Gorin: Evidence, ethics, and youth gender dysphoria

Professor Moti Gorin, a philosopher specialising in autonomy and medical ethics, was lead author of the ethics chapter of the US HHS evidence review. He applied principlism, the dominant framework in medical ethics set out by Tom L. Beauchamp and James F. Childress in Principles of Biomedical Ethics, to paediatric medical transition. Its four principles are non-maleficence, beneficence, respect for autonomy and justice.

He set out two competing rationales. The traditional rationale holds that transition relieves distress and improves health. It underpins the Dutch studies, the DSM-5 diagnosis and claims by bodies such as the AMA and WPATH. Under principlism it needs a favourable balance of benefits and harms. Yet the evidence of benefit is “threadbare”, while harms such as loss of fertility are well established.

Gorin argued that advocates are now shifting the goalposts to a “gender embodiment goals” rationale, under which treatment is justified simply by changing the body as the patient wishes, with no claim to improve health. He cited Florence Ashley, Andrea Long Chu, a recent paper co-authored by Annelou de Vries and the ICD-11 diagnosis of gender incongruence.

He said appeals to autonomy can’t rescue this rationale. Autonomy is a negative right to refuse treatment, not a right to demand it, because “doctors are not vending machines”. Advocates must either produce better evidence of health benefit or explain how a minor’s current wishes about their body can justify invasive treatment.

Alison: Ethical dilemmas for parents of children who identify as trans

Alison, a parent and an NHS “expert by experience”, said gender medicine has had too much lived experience and too little science. Lived experience can, however, be a “canary in the coal mine”, as when she noticed the sudden rise in trans-identifying teenagers in the mid-2010s. Parents try to keep all of a child’s options open, but they swim against the tide. In a survey by the Bayswater Support Group, 67% of parents said their child had been socially transitioned at school and 83% by friends. Some 11% had been referred to social services, mostly on unfounded grounds. Another 28% said a professional had encouraged medical transition against their wishes, and 20% were estranged from their child. Parents are often the only adults showing any curiosity about what the new identity means.

The main UK research projects, which are Pathways, the James Lind Alliance priority-setting partnership and Bristol’s evidence reviews, all start from an undefined “mismatched gender identity”. Bristol consults trans youth but not detransitioners. The James Lind Alliance excludes the causes of gender incongruence. Pathways leaves trial eligibility to the clinical service. She warned that parents risk the same “grave misunderstandings” the Cass Review found at GIDS, and called for genuine curiosity about the underlying condition.

Day two: Social and cultural contexts, clinical perspectives

Society, culture and detransition (chair: Professor David Pilgrim)

Stephanie Davies-Arai: Social transition. What’s the harm?

Stephanie Davies-Arai, founder of Transgender Trend, has worked with parents and schools on communication skills for over 20 years. She argued that social transition in childhood is neither harmless nor neutral, and may not be reversible. Children should be viewed through child development and safeguarding, not adult frameworks of rights and equality. Social transition gives children attention and approval, and behaviour that is rewarded is repeated. It should be seen as the first step on the transition pathway. Studies by Steensma and Olson and the Cass Review’s systematic review link it to persistence of a trans identity.

She cited a case Hilary Cass raised in the House of Lords. A boy raised as a girl from early childhood now, at 11, rarely leaves his room. Young children cannot understand gender identity. They absorb what adults tell them, which risks creating a “false self” (Winnicott). Adolescents are in a critical period of identity formation. Foreclosing identity early risks instability, and most detransitioners transitioned socially as adolescents.

Social transition also places demands on other children. She described girls at a primary school who were distressed after learning a classmate was a boy, and teenage girls taught to ignore their boundaries. She called both a serious safeguarding concern.

Dr Sarah Mittermaier: Beliefs about medical transition and the body in online trans spaces

Dr Sarah Mittermaier argued that beneath the false beliefs about medical transition circulating in online trans spaces lies a “disembodied mentality”. It treats the body as an endlessly malleable object. Young people describe being trans as a “hardware problem” and talk of bodies that change like video-game avatars. In this view, hormones are an “installation package” the body will follow in either direction.

These metaphors have clinical consequences. If distress is seen as a physical defect, only changing the body can relieve it, and alternatives are shut down. Online, hormones and surgery are presented as low-stakes and reversible. Risks are dismissed, concerns about lifelong medicalisation are labelled ableist, and young people learn how to get past safeguards. Transition can become a rite of passage or a way to silence doubt. Some seek surgery to “remove the question itself”.

With WPATH listing 57 surgical procedures, one intervention often leads to another, and “the finish line retreats”. Drawing on Ivan Illich, she suggested that making puberty optional has made it intolerable. Many young people’s hopes are impossible, and some feel “sold a lie”. She closed by asking what it would mean to take the body seriously, not as hardware to upgrade but as the reality a young person will live in for life.

Michael Kerr: Detransition pathways. Going back but moving forward

Michael Kerr, 34, described seven years of transition, five of them on oestrogen. He spent two years waiting for an NHS appointment, under strong pressure from the trans community to conform. His assessment at Sandyford Gender Clinic was brief. He said its diagnostic notes rested on sexist and homophobic stereotypes, such as wearing makeup and not liking football as a child.

After one euphoric year on hormones, doubts set in. He gained five stone and developed joint and chronic pain problems. Each time he raised his unease, clinicians told him it was normal and that surgery would help. Past trauma, alcohol and drug use, he reflected, had fed into his wish to transition.

In May 2025 he stopped hormones. His fifth Sandyford doctor couldn’t answer basic questions about coming off them. He said that, unlike other NHS treatment, transition has no off-ramp. A difficult period followed, which he got through with his family’s support and therapy.

Kerr said detransitioners are invisible to the NHS: untracked, undiagnosed and without services, and the promised NHS pathway has yet to appear. He founded Detransition Pathway UK (www.detranspathway.com), which has supported about 25 detransitioners, all female. He criticised research groups for including detransitioners in name only.

Dr Stella O’Malley: Beyond Trans. What kind of support do detransitioners need?

Dr Stella O’Malley, a psychotherapist, described several years of running online support groups. She stressed that the data she presented was observational and that the priority had been helping people, not research.

The parent groups, modelled on Al-Anon, began in March 2020 and have supported over 5,000 parents, more than 90% of them mothers. Parents can choose peer-led or therapist-led groups. There are separate groups for parents of medicalised or estranged children. A new group supports wider family members.

The Beyond Trans detransition support group (https://beyondtrans.org) began in 2022 by funding individual psychotherapy. O’Malley moved it to peer groups. The groups have now helped over 600 people. Her own groups, with 167 members, are 62% female. Of those members, 63% have detransitioned, 9% regret transition, 9% are still medicalised and 19% never medicalised. Most were unsure of or did not disclose their sexual orientation. Many have trauma and mental health problems.

On average, members transitioned at 23 and detransitioned at 32, though some detransition in their 60s or later. Their quotes described constant “performing”, poor informed consent and feeling like survivors of medical malpractice.

Psychotherapy (chair: Dr David Bell)

Anastassis Spiliadis: Embodied distress in adolescence

Anastassis Spiliadis, a clinical psychologist, challenged the view that psychotherapy for gender-related distress is inherently conversion therapy. That view, he argued, arose after homosexuality was depathologised and wrongly groups all approaches together, including modern psychoanalytic, CBT and family therapies. Many European countries now recommend psychosocial interventions first, but rarely define them. The University of York review found no evidence that contemporary psychotherapy causes harm, and no high-quality evidence that it works.

He suggested lessons from eating disorders and body dysmorphic disorder, where NICE recommends family therapy or CBT with parents involved, backed by decades of trials and clear outcome measures. For gender-related distress, he proposed outcomes such as reduced distress, better functioning, better quality of life and stronger family relationships. For some, a good outcome may also mean not seeking hormones or surgery. Eating disorders often occur alongside gender distress. Blocking puberty in a starving adolescent risks “double blocking” and serious harm to bone health, so life-threatening illness should be treated first. He emphasised engaging parents, encouraging their curiosity, repairing family ruptures and avoiding “culture wars” in the therapy room. Psychotherapy now needs clearly defined models, fidelity and proper research with established institutions.

Dr Anna Hutchinson: Psychotherapeutic work with gender-distressed youth (part one)

Dr Anna Hutchinson, a clinical psychologist, argued that care for gender-distressed young people must move from a biosocial to a biopsychosocial approach. Psychologists are the largest professional group in gender services, yet they have been strangely absent from the debate. The ICD-11 criteria describe subjective experiences, which are psychology’s home ground. Cognitive, psychodynamic, systemic and neurodevelopmental models agree that identity is dynamic, built in relationship with others, serves a purpose and takes shape in adolescence. A trans identity is understandable within these models. But no tool can predict a person’s future identity, and adolescence is the worst time to try.

Gender-affirming care, she said, is a tool rather than a developmentally informed model. It assumes identity is fixed and self-defined, and risks shaping identities rather than simply treating them. Not affirming carries risks too, so therapists must connect with the young person’s experience. Psychotherapy affirms experience without confirming or disconfirming beliefs, as it does with a depressed patient convinced they are worthless. It is open-ended, collaborative and consensual, unlike coercive conversion therapy. Discomfort in therapy should not be mistaken for harm. Trans adolescents are adolescents, and what is exceptional is how society and medicine respond to them. She ended by saying that good psychotherapy can also be life-saving.

Dr Celia Sadie: Psychotherapeutic work with gender-distressed youth (part two)

Dr Celia Sadie, a clinical psychologist, described coming to this field relatively recently. In a decade on adolescent inpatient units, where patients were suicidal, anorexic or psychotic, she saw no trans-identified young person until 2014. In ten years in youth prisons, no boy identified as trans. When a gender identity question was added to intake assessments, the boys were baffled, and she wondered whether asking it was itself putting the idea in their minds. In private practice since 2024, most of the families contacting her have been in crisis over gender identity.

Adolescents often arrive at therapy with a ready-made solution, as with anorexia, but there is always ambivalence to work with. She described the chilling effect: brain fog, fear and pressure to take sides. A therapist who reaches for certainty becomes useless, even dangerous. No ethical therapy can aim at conversion in any direction. Transition often offers a concrete fix for adolescent shame and existential fear. Explored with curiosity, it may reflect a struggle to grow up, anger at parents, a wish to belong, same-sex attraction in a homophobic setting or fear of adult sexuality. She stressed preserving family bonds, criticised the British Psychological Society’s silence and urged psychologists to be brave and “jump in”.

Dr Stephen Levine: Working psychotherapeutically with families of gender-distressed youth

Dr Stephen Levine, a psychiatrist, offered concepts to help therapists support parents. A child’s new identity is a crisis, both a danger and an opportunity. Parents feel fear, guilt, blame, anger and betrayal. Therapists should let parents talk and help them name their feelings. Parents are not transphobic but “trans-wary”. The aims are to preserve the bond between parent and child and, together, to understand the factors behind the new identity.

He proposed a deal. Parents try to respect the new name and pronouns, the young person respects the parents’ long history with them, and both keep talking, because “the next 70 years” are at stake. Parents should be honest that they don’t think this is good for their child. Adolescents are certain, passionate, secretive, easily influenced and changeable. Levine described a new trans identity as a private, creative, partly unconscious and often maladaptive solution to existential pain. He set out predisposing, precipitating and maintaining factors, from autism and trauma to online communities. A prepared, connected parent, he concluded, may help more than any therapist.

Clinical perspectives (chair: Dr Aileen O’Brien)

Dr Louise Irvine: Uncertainty and risk. Should general practitioners prescribe cross-sex hormones?

Dr Louise Irvine, a retired GP and Co-Chair of CAN-SG, spoke about the uncertainty and risk GPs face when patients ask for cross-sex hormones. She described a former patient who, despite repeated hormone adjustments and surgery, remained depressed and isolated. That case led her to question what gender-affirming treatment is meant to achieve.

She found no evidence base and no UK clinical guidelines for this care. The NHS adult gender service specification still relies on WPATH’s SOC 7. The only research on GP gender care is two audits, Boyd et al. and Silver et al. The Levy Review found adult gender clinics collected no patient outcome data.

Despite this, GPs are under pressure to prescribe. “Bridging prescriptions,” backed by the GMC as harm reduction, have allowed some GPs to become self-styled experts with no audit or oversight. The WellBN clinic in Brighton was suspended after prescribing to thousands, including children. The Levy Review now proposes discharging patients to GPs with extended roles. This comes as patient numbers grow and the patient group becomes younger, more female and more complex.

Irvine noted that GMC guidance makes prescribers responsible for safety and lets them decline. She concluded that GPs should not start or bridge hormones, should be cautious about long-term care, and that the extended GP role lacks an evidence base.

Dr Katie Alcock: The link between autism spectrum disorders and gender-related distress

Dr Katie Alcock, Senior Lecturer in Psychology at Lancaster University, presented the second phase of her research on why autism and gender dysphoria so often occur together. One large US military health study found autistic children were four times as likely to be diagnosed with gender dysphoria. Existing explanations are weak. One holds that autistic people mentalise less and so care less about conforming, but that does not explain why they would feel more distress. Simon Baron-Cohen’s “extreme male brain” theory has little evidence, relies largely on his own instruments and is circular. Purely social explanations sit awkwardly with the evidence of social contagion.

Her team built a battery of measures covering empathy, theory of mind, systemising, mental rotation, need for cognitive closure (difficulty tolerating uncertainty) and gender stereotyping. Earlier work found autistic young people had more difficulty separating appearance from reality. In the new data, Baron-Cohen’s measures, including the “Reading the Mind in the Eyes” test that previous studies rely on, performed poorly. More reliable measures showed that systemising and need for cognitive closure were both linked to stereotyping, which is a new finding. Men rated themselves as better at systemising but did no better on mental rotation. The next step is to shorten the tests and model the links. Links between autistic traits and gender dysphoria traits have been found, but no explanatory factors yet.

Elaine Miller: Pelvic floor complications of testosterone use in women and how physiotherapy can help

Elaine Miller, a pelvic health physiotherapist, noticed young women on testosterone coming to her clinic with incontinence and pelvic problems typical of menopausal women 30 years older. Continence matters deeply to quality of life, yet gender clinics provide no information about these effects. One study found 69% of trans-identified adolescents on testosterone reported pelvic pain, but only one in five attended the physiotherapy offered. With Professor Ruth Parry, she reviewed the evidence and consulted trans-identified people and detransitioners. They used sex-based language, and she suggested terms such as “masculinised female” so as not to imply sex can change.

After vaginoplasty, up to 15% of males are incontinent and 75% report sexual dysfunction. After phalloplasty, up to 50% of females are incontinent. She said a neophallus made from forearm tissue can never function as a penis. The studies come largely from the clinics themselves and are short-term, so harms are likely underreported. She compared this with the vaginal mesh scandal. There is no research on physiotherapy for this group, none at all on females, and no physiotherapy after gender-related mastectomy, which may leave shoulder problems. Many young trans-identified people also have chronic pain or use self-bought mobility aids. Pelvic health services sometimes refuse referrals, saying “we don’t treat gender”. Gender is not special, she argued, and physiotherapy should be offered in gender clinics and in the community.